Apomorfín

Apomorphine is primarily used to treat acute hypomobility episodes in advanced Parkinson's disease. Despite its name, it does not contain morphine and does not bind to opioid receptors. Nausea is extremely common; antiemetic pretreatment with trimethobenzamide or domperidone is typically required. Contraindicated with 5-HT3 antagonists due to severe hypotension risk. Contains sulfites which may cause allergic reactions in sensitive individuals.

Also known as: Apokyn, Onapgo, Apo-go, Ixense, Uprima, Apo-Go PEN, Apo-Go pump, Movapo

Classification

Chemical: Medicine
Tag: Aporphine
Tag: Dopaminergic
Tag: Pharmaceutical

Effects

Relief Of Parkinsonian Symptoms
Nausea
Vomiting
Yawning
Orthostatic Hypotension
Sudden Sleep Onset
Drowsiness
Dizziness
Compulsive Behaviors
Hallucinations
Open Eye Visuals

Routes of Administration

Subcutaneous

Dosage

Threshold: 0.5-1 mg
Light: 1-2 mg
Common: 2-6 mg
Strong: 6-10 mg
Heavy: ≥10 mg (not recommended without specialist supervision)

Duration

Onset: 0.08-0.33 h
Comeup: 0.17-0.25 h
Peak: 0.33-1 h
Offset: 0.5-1 h
After Effects: 2-3 h
Total Duration: 1-2 h

Sublingual

Dosage

Light: 10–15 mg
Common: 10-20 mg
Strong: 20-30 mg
Heavy: >30 mg (not recommended)
Threshold: ~10 mg

Duration

Onset: 0.17-0.33 h
Comeup: 0.25-0.5 h
Peak: 0.5-1.5 h
Offset: 0.5-1 h
After Effects: 2-4 h
Total Duration: 1.5-3 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu